OAM
AQST icon

Oxford Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Oxford Asset Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-41,415
Closed -$232K – 495
2025
Q3 		$232K Buy
+41,415
New +$179K 0.08% 370
2020
Q1 		$30K Sell
13,660
-297,879
-96% -$1.13M ﹤0.01% 176
2019
Q4 		$1.81M Buy
311,539
+239,243
+331% +$1.24M 0.05% 474
2019
Q3 		$230K Buy
72,296
+48,647
+206% +$182K 0.01% 1541
2019
Q2 		$99K Sell
23,649
-86
-0.4% -$440 ﹤0.01% 1614
2019
Q1 		$164K Sell
23,735
-15,231
-39% -$107K ﹤0.01% 1535
2018
Q4 		$245K Sell
38,966
-7,957
-17% -$100K 0.01% 1473
2018
Q3 		$816K Buy
+46,923
New +$773K 0.02% 1101

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oxford Asset Management's AQST Position: Q4 2025 in Review

Oxford Asset Management sold out of Aquestive Therapeutics (AQST) in Q4 2025, closing a stake of 41,415 shares — an estimated $232K sold.

Oxford Asset Management first reported a position in AQST in Q3 2018 and held it in 8 quarters. The position peaked at $1.81M in Q4 2019. 176 funds tracked by Wall St. Rank hold AQST as of Q4 2025.

  • Oxford Asset Management reported no remaining Aquestive Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Oxford Asset Management sold 41,415 Aquestive Therapeutics shares in Q4 2025, an estimated $232K.
  • Oxford Asset Management first reported a position in Aquestive Therapeutics in Q3 2018 and held it in 8 quarters.
  • Oxford Asset Management's Aquestive Therapeutics position peaked at $1.81M in Q4 2019.
  • 176 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2025.

Based on Oxford Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.